Loading organizations...
Virtus Ventures Group offers specialized international financial consulting and funding services, guiding projects and businesses through complex global markets. The firm crafts tailored strategies and provides expert insights for equity and debt financing, utilizing comprehensive due diligence to maximize client value. Capabilities span diverse sectors like commercial real estate, healthcare, and energy, serving clients globally.
Established to address demand for sophisticated financial navigation in a globalized economy, Virtus Ventures Group operates with strong professionalism. The firm leverages its team's collective international finance experience, positioning them as a key resource. This expertise enables businesses and projects to access strategic funding and navigate global capital.
The firm serves a broad clientele of businesses and project developers seeking international growth or expansion. Virtus Ventures Group’s vision is to be a pivotal partner, empowering clients to achieve financial goals by simplifying cross-border transactions. Their mission focuses on facilitating sustained global expansion and success for a diverse project portfolio.
Virtus Ventures has 2 tracked investments across 1 company. The latest tracked deal is $53.0M Other Equity in Rani Therapeutics in February 2018.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 8, 2018 | Rani Therapeutics | $53.0M Other Equity | — | AstraZeneca, Bossa Ventures, Cathay Venture, GeneScience Pharmaceuticals, GV, Novartis, Ping AN Ventures, Shire |
| Feb 1, 2018 | Rani Therapeutics | $53.0M Series U | — | Byers Capital, Founders' Co OP, Seven Seven SIX, Susa Ventures, Y Combinator, Justin Mateen, AstraZeneca, Bossa Ventures, Cathay Venture, GeneScience Pharmaceuticals, GV, Novartis, Ping AN Ventures, Shire |
